New Zealand markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.3200-0.1500 (-3.36%)
At close: 04:00PM EDT
4.4100 +0.09 (+2.08%)
After hours: 05:09PM EDT

G1 Therapeutics, Inc.

700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835
https://www.g1therapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees100

Key executives

NameTitlePayExercisedYear born
Mr. John E. Bailey Jr.CEO, President & Director1.06MN/A1965
Mr. Mark AvaglianoChief Business Officer628.54kN/A1976
Mr. John W. Umstead VChief Financial OfficerN/AN/A1985
Mr. Terry L. MurdockChief Operating Officer541.59k606.34k1960
Mr. William C. RobertsVice President of Investor Relations & Corporate CommunicationsN/AN/A1969
Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerN/AN/AN/A
Mr. Evan Hicks M.B.A.Vice President of MarketingN/AN/AN/A
Dr. Rajesh K. Malik Ch.B., M.B., M.D.Chief Medical Officer596.37k1.48M1959
Mr. Andrew PerryChief Commercial Officer568.6kN/A1973
Mr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Corporate governance

G1 Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.